Cytokinetics Incorporated  (CYTK)
Other Ticker:  
Price: $78.0200 $2.43 3.215%
Day's High: $79.49 Week Perf: 1.47 %
Day's Low: $ 75.86 30 Day Perf: -4.59 %
Volume (M): 1,739 52 Wk High: $ 110.25
Volume (M$): $ 135,646 52 Wk Avg: $42.70
Open: $76.00 52 Wk Low: $25.98

 Market Capitalization (Millions $) 7,480
 Shares Outstanding (Millions) 96
 Employees 202
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -527
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 5

Cytokinetics Incorporated
Cytokinetics Incorporated is a biopharmaceutical company that is dedicated to developing small molecule drugs that can be used to treat a variety of diseases. The company was founded in 1997 and is headquartered in South San Francisco, California. Since its inception, Cytokinetics has focused on developing drugs that can enhance the function of the muscles in the body, with an emphasis on skeletal and cardiac muscle.

Cytokinetics has developed a number of investigational drugs that are intended to improve the function of the heart and skeletal muscles. The company has developed a drug called omecamtiv mecarbil that is intended to improve the contractility of cardiac muscle. This drug is currently being tested in several clinical trials for the treatment of heart failure. Cytokinetics has also developed a drug called reldesemtiv that is intended to improve skeletal muscle function in people with amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).

In addition to its investigational drugs, Cytokinetics has developed a number of partnerships with other companies and academic institutions. The company has partnered with companies like Amgen and Astellas to advance and develop its investigational drugs. It has also worked with academic institutions like the University of California, San Francisco and the University of Michigan to further explore the science behind its drug development.

Cytokinetics has received numerous grants and awards for its drug development efforts. In 2013, the company received a grant from the National Institute of Neurological Disorders and Stroke to support the development of reldesemtiv for the treatment of ALS. The company has also been recognized by the California Institute for Regenerative Medicine for its work in developing cell therapy approaches for heart disease.

Overall, Cytokinetics has established itself as a leader in the development of drugs that can improve muscle function in a variety of diseases. Its investigational drugs have the potential to improve patient outcomes and benefit the field of medicine as a whole.

   Company Address: 350 Oyster Point Blvd South San Francisco 94080 CA
   Company Phone Number: 624-3000   Stock Exchange / Ticker: NASDAQ CYTK
   CYTK is expected to report next financial results on February 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Cytokinetics Allocates $100,000 in Annual Communications Grant to Boost Patient Advocacy Outreach

Published Mon, Jan 29 2024 12:30 PM UTC

Cytokinetics, the renowned pharmaceutical company, has announced the recipients of its Sixth Annual Communications Grant Program. In a noteworthy philanthropic step, a total of $100,000 has been awarded to five chosen patient advocacy organizations. This funding is aimed at strengthening their communications and enabling them to enhance their community outreach efforts more ...

Clinical Study

Cytokinetics Presents Promising Data on Aficamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy and Updates on Reldesemtiv's Efficacy in ALS

Published Thu, Jan 25 2024 12:30 PM UTC

Cytokinetics, a leading biopharmaceutical company specializing in the development of novel therapies for cardiovascular and neuromuscular diseases, recently presented new data at CMR 2024 regarding the clinical trial of Aficamten in patients with obstructive hypertrophic cardiomyopathy. These findings demonstrate favorable structural remodeling, improvements in cardiac funct...

Clinical Study

Paving the Way for Groundbreaking Treatment: Aficamten's Triumph in Obstructive Hypertrophic CardiomyopathyDisclaimer: This article is not intended to replace professional medical advice. Always consult with healthcare professionals before making any treatment decisions.

Published Wed, Dec 27 2023 12:30 PM UTC

Abstract:Obstructive hypertrophic cardiomyopathy (HCM) is a complex and potentially life-threatening cardiac disorder affecting a significant proportion of the global population. In recent years, there has been a growing need to identify effective treatment options to alleviate symptoms and improve patient outcomes. This article aims to provide an extensive analysis of the S...

Clinical Study

Hope Dashed for ALS Patients: Cytokinetics' COURAGE-ALS Study Fails to Show Promise in Halting Functional Decline

Published Thu, Dec 7 2023 12:30 PM UTC

In a recent press release, Cytokinetics, a leading biopharmaceutical company, unveiled the results from its renowned clinical trial, COURAGE-ALS, at the 34th International Symposium on ALS/MND. The highly anticipated study examined the potential of reldesemtiv, a novel therapeutic compound, to demonstrate positive effects on the functional decline assoc...

Cytokinetics Incorporated

Cytokinetics Incorporated shows promising signs of growth with reduced losses in fiscal year 2023

The stock market can be a roller coaster ride, filled with highs and lows, but amidst the unpredictability, there are still reasons to be optimistic. Despite facing some challenges, Cytokinetics Incorporated has shown signs of resilience and potential for growth in the coming months.
In the fiscal interval closing September 30, 2023, Cytokinetics Incorporated experienced a decrease in its losses. The loss per share decreased from $-1.52 to $-1.35 compared to the previous year, showcasing the company's efforts to improve its financial performance. Additionally, the deficit was reduced from $-1.34 per share in the prior quarter, indicating progress in the right direction.


Cytokinetics Incorporated's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com